Precision Medicine for Every Child With Cancer

Summary

To improve outcomes for childhood cancer patients through the implementation of precision medicine.

Conditions

• Childhood Cancer
• Childhood Solid Tumor
• Childhood Brain Tumor
• Childhood Leukemia
• Refractory Cancer
• Relapsed Cancer

Interventions

GENETIC

Whole Genome Sequencing

Each tumor sample will be sequenced and analyzed in parallel with its matched normal (germline DNA from the same patient) to enable the identification of somatic aberrations.

GENETIC

RNA seq

Results will be used for bioinformatics analysis for fusion transcripts and gene expression.

GENETIC

DNA Methylation

Genome-wide assessment of DNA methylation will be conducted on all samples where possible.

GENETIC

Targeted Panel Sequencing

Targeted panel sequencing may be performed: 1. When WGS is not feasible or appropriate, e.g., insufficient DNA from fresh or frozen sample or only Formalin-Fixed Paraffin-Embedded (FFPE) material is available 2. When mosaicism is suspected 3. When indicated for a disease type

GENETIC

High Throughput Sequencing (in vitro)

High throughput drug screening will be attempted for tumors from Cohort 1 (high-risk cancers with survival \<30%) and selected tumor types.

GENETIC

Patient Derived Xenograft (PDX)(in vivo)

In vivo drug testing in patient derived xenograft (PDX) will be attempted for tumors from Cohort 1 (high-risk cancers) and selected tumor types.

OTHER

Liquid Biopsy

Liquid biopsy will be investigated as a non-invasive method for diagnosis of tumors that are difficult to biopsy directly, understanding tumor heterogeneity, monitoring of treatment response, and detection of minimal residual disease (MRD)/relapse in leukemia, solid and CNS tumors.

Sponsors & Collaborators

• Children's Cancer Institute (CCI)

  collaborator UNKNOWN

• Minderoo Foundation

  collaborator UNKNOWN

• Medical Research Future Fund

  collaborator OTHER

• Australian & New Zealand Children's Haematology/Oncology Group

  lead OTHER

Principal Investigators

• David Ziegler · SCHN

Eligibility

Min Age

0 Years

Max Age

25 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2022-12-16

Primary Completion

2025-07-31

Completion

2030-07-31

Countries

• Australia
• New Zealand

Study Locations